Social Anxiety Disorder
ATAIATAI Life SciencesCatalyst overview
Research summary
This catalyst tracks a Phase 2a update for EMP-01 (3,4-methylenedioxy-methamphetamine [MDMA] derivative) in Social Anxiety Disorder. The expected timing is based on the latest available company guidance and may change.
1/2/24- Positive Ph1 topline results. Q4 '24- Initiated Ph2 trial. 5/13/25- First patient dosed with topline data in Q1 2026. 12/01/25:- Completed enrollment in the exploratory Ph2a SAD trial; topline results remain expected in Q1 2026. 02/26/26:- Reported topline positive Ph2a SAD trial results; more detailed analyses planned at upcoming scientific meetings. 03/06/26:- Ph2a SAD trial detailed topline efficacy metrics reported; new US patent extends EMP-01 exclusivity to 2043. 04/22/26:- Expanded Ph2a NCT06693609 results showed SPIN and SAFE improvements; no SAEs. 05/12/26:- Ph2a SAD results showed consistent improvements across clinician, patient and real-world behavioral outcomes.
Verification
Confirm timing and program details against the company announcement or filing.